<DOC>
	<DOCNO>NCT00418483</DOCNO>
	<brief_summary>The purpose study evaluate safety increase dos intra-thrombus Plasmin ( Human ) acute peripheral arterial occlusion ( aPAO ) . The ability Plasmin dose dissolve clot estimate arteriography .</brief_summary>
	<brief_title>A Dose Escalation Safety Study Plasmin ( Human ) In Acute Lower Extremity Native Artery Bypass Graft Occlusion</brief_title>
	<detailed_description>There unmet need proven thrombolytic agent acute peripheral arterial occlusion ( aPAO ) . The current assortment plasminogen activator slow dissolve clot leg , may lead bleed complication . Plasmin direct thrombolytic may act quickly infuse directly clot thus assist restore blood flow leg . There large reserve blood alpha-2 antiplasmin blood rapidly inactivate Plasmin outside clot . Plasmin potential improve bleeding risk profile aPAO .</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Fibrinolysin</mesh_term>
	<criteria>Age ≥ 18 year . Women childbearing potential must use adequate contraception duration study must negative pregnancy test prior study entry . Unilateral limb ischemia : SVS acute ischemia Category I IIa . Onset symptom &lt; /= 14 day . Thrombosed ( nonembolic ) infrainguinal graft ( synthetic , autologous , single outflow composite ) infrainguinal native artery . For native artery , occlusion ≥ 10 cm length eligible . Diagnosis occlusive thrombus graft artery arteriography Informed Consent obtain . Ability traverse thrombus guidewire . Signed informed consent prior study entry . Clinical evidence significant disease may interfere patient successfully complete trial . Women pregnant lactating , first 10 day postpartum . Previous hemorrhagic stroke time . Thrombotic embolic stroke cerebrovascular event ( include transient ischemic attack ( TIA ) ) within one year . Intracranial spinal neurosurgery , severe intracranial trauma last 3 month . Major surgery , organ biopsy , major trauma within last 10 day . Lumbar puncture noncompressible arterial puncture last 10 day . Intraocular surgery within last 10 day . Current bleeding diathesis . Active gastrointestinal organ bleed . Minor bleed normal menses , cystitis , minor hemorrhoidal bleeding exclusion . Uncontrolled arterial hypertension , define systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg . Known intracranial neoplasm , aneurysm , arteriovenous malformation . Platelet count &lt; 75 x 10e9/L . Occlusion graft within 6 month placement . Medically unable tolerate open vascular procedure . Known prothrombotic condition . Hemoglobin &lt; 10.0 g/dL Impaired renal function renal disease constitute contraindication contrast angiography , include creatinine &gt; 2.0 mg/dL subject renal dialysis . Treatment glycoprotein IIb/IIIa class platelet inhibitor within past 5 day , example , abciximab ( ReoPro® ) , eptifibatide ( Integrilin® ) tirofiban ( Aggrastat® ) . Treatment warfarin ( Coumadin® ) INR &gt; 1.7 ( elevate INR screening may correct prior study enrollment . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>thrombolytic</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>acute peripheral arterial occlusion</keyword>
	<keyword>peripheral vascular disease</keyword>
	<keyword>thrombosis</keyword>
	<keyword>endovascular</keyword>
</DOC>